Jan. 11, 2018—Illumina announced Tuesday the launch of its iSeq 100 Sequencing System, a next-generation sequencing system that aims to deliver exceptional data accuracy at a low capital cost—the U.S. list price is $19,900. The system combines the company’s sequencing by synthesis chemistry and complementary metal-oxide-semiconductor detection technology and represents an entirely different configuration, the company said.
“The addition of the iSeq 100 has great potential to transform infectious disease surveillance,” Pardis Sabeti, DPhil, MD, professor of immunology and infectious diseases at Harvard T.H. Chan School of Public Health and member of the Broad Institute, said in a press release from Illumina. “We anticipate that our lab researchers will use it to focus on infectious disease monitoring. We have seen examples of how Illumina benchtop systems, like the MiSeq, were instrumental in understanding and addressing disease outbreaks. We believe the accuracy of the iSeq 100, coupled with the low cost and small footprint, will allow us to introduce NGS capability where it is needed most.”
Measuring one cubic foot, the iSeq 100 delivers NGS discovery power in the most compact format of any Illumina sequencer to date.
The company also announced it signed a commercial agreement with Thermo Fisher Scientific. Under the agreement, Thermo Fisher will provide Illumina with Ion AmpliSeq technology for research use. Illumina will sell the product directly to its customers under the name AmpliSeq for Illumina. The amplicon technology is highly effective in capturing DNA and RNA from minute amounts of samples for application in multiple areas of research. The agreement enables Illumina customers to utilize targeted resequencing as a follow-up to larger-scale exome and whole genome discovery studies.